Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma
This study is currently recruiting participants.
Verified January 2013 by University of Nebraska
Sponsor:
University of Nebraska
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
Julie M Vose, MD, University of Nebraska
ClinicalTrials.gov Identifier:
NCT01431209
First received: September 5, 2011
Last updated: January 8, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | August 2025 |
| Estimated Primary Completion Date: | August 2016 (Final data collection date for primary outcome measure) |